BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27662198)

  • 1. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.
    Ford J; Thuro BA; Thakar S; Hwu WJ; Richani K; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2017; 33(4):e82-e85. PubMed ID: 27662198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
    Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
    JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Biological Drugs and Immune Check Point Inhibitors for Locally Advanced or Metastatic Cancers of the Conjunctiva, Eyelid, and Orbit.
    Esmaeli B; Sagiv O
    Int Ophthalmol Clin; 2019; 59(2):13-26. PubMed ID: 30908276
    [No Abstract]   [Full Text] [Related]  

  • 5. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
    Ivashko IN; Kolesar JM
    Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Pagès C; Baroudjian B; Lebbé C
    Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
    Harvey NT; Millward M; Macgregor K; Bucat RP; Wood BA
    Am J Dermatopathol; 2016 Dec; 38(12):e159-e162. PubMed ID: 27870733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scleroderma Induced by Pembrolizumab: A Case Series.
    Barbosa NS; Wetter DA; Wieland CN; Shenoy NK; Markovic SN; Thanarajasingam U
    Mayo Clin Proc; 2017 Jul; 92(7):1158-1163. PubMed ID: 28599746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy.
    Chang M; Lally SE; Dalvin LA; Orloff MM; Shields CL
    Indian J Ophthalmol; 2019 Dec; 67(12):2071-2073. PubMed ID: 31755463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Roncati L
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better.
    Atrash S; Makhoul I; Mizell JS; Hutchins L; Mahmoud F
    J Oncol Pharm Pract; 2017 Apr; 23(3):215-219. PubMed ID: 26811403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune and molecular correlates in melanoma treated with immune checkpoint blockade.
    Byrne EH; Fisher DE
    Cancer; 2017 Jun; 123(S11):2143-2153. PubMed ID: 28543699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
    Hamid O
    Clin Adv Hematol Oncol; 2014 Nov; 12(11):782-4. PubMed ID: 25674719
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.